UCB BIOSCIENCES, Inc.
29
0
2
21
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 20/100
13.8%
4 terminated/withdrawn out of 29 trials
84.0%
-2.5% vs industry average
38%
11 trials in Phase 3/4
105%
22 of 21 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (29)
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
Role: lead
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
Role: lead
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
Role: lead
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
Role: lead
Doxecitine and Doxribtimine-Expanded Access
Role: lead
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
Role: lead
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
Role: lead
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
Role: lead
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
Role: lead
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
Role: lead
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056
Role: lead
An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy
Role: lead
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
Role: lead
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
Role: lead
UCB Cimzia Pregnancy Follow-up Study
Role: lead
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Role: lead
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
Role: lead
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
Role: lead
Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures
Role: lead
Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
Role: lead